Abstract
A major predictor of the efficacy of natural or synthetic cannabinoids is their binding affinity to the cannabinoid type I receptor (CB1) in the central nervous system, as the main psychological effects of cannabinoids are achieved via binding to this receptor. Conventionally, receptor binding assays have been performed using isotopes, which are inconvenient owing to the effects of radioactivity. In the present study, the binding affinities of five cannabinoids for purified CB1 were measured using a surface plasmon resonance (SPR) technique as a putative non-isotopic receptor binding assay. Results were compared with those of a radio-isotope-labeled receptor binding assay. The representative natural cannabinoid Δ9-tetrahydrocannabinol and four synthetic cannabinoids, JWH-015, JWH-210, RCS-4, and JWH-250, were assessed using both the SPR biosensor assay and the conventional isotopic receptor binding assay. The binding affinities of the test substances to CB1 were determined to be (from highest to lowest) 9.52 × 10−13 M (JWH-210), 6.54 × 10−12 M (JWH-250), 1.56 × 10−11 M (Δ9-tetrahydrocannabinol), 2.75 × 10−11 M (RCS-4), and 6.80 ×10−11 M (JWH-015) using the non-isotopic method. Using the conventional isotopic receptor binding assay, the same order of affinities was observed. In conclusion, our results support the use of kinetic analysis via SPR in place of the isotopic receptor binding assay. To replace the receptor binding affinity assay with SPR techniques in routine assays, further studies for method validation will be needed in the future.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Karila, L., Benyaminia, A., Blecha, L., Cottencin, O. and Billieux, J. (2016) The synthetic cannabinoids phenomenon. Curr. Pharm. Des., 22, 6420–6425.
Scocard, A., Benyamina, A., Coscas, S. and Karila, L. (2017) Synthetic cannabinoids: A new addiction matrix. Pres. Méd., 46, 11–22.
Tournebize, J., Gibaja, V. and Kahn, J.P. (2016) Acute effects of synthetic cannabinoids: update 2015. Subst. Abuse, 11, 1–23.
Paulke, A., Proschak, E., Sommer, K., Achenbach, J., Wunder, C. and Toennes, S.W. (2016) Synthetic cannabinoids: In silico prediction of the cannabinoid receptor 1 affinity by a quantitative structure-activity relationship model. Toxicol. Lett., 245, 1–6.
Maida, V. and Daeninck, P.J. (2016) A user’s guide to cannabinoid therapies in oncology. Curr. Oncol., 23, 398–406.
Androvicova, R., Horacek, J., Stark, T., Drago, F. and Micale, V. (2017) Endocannabinoid system in sexual motivational processes: Is it a novel therapeutic horizon? Pharmacol. Res., 115, 200–208.
Ford, B.M., Tai, S., Fantegrossi, W.E. and Prather, P.L. (2017) Synthetic pot: not your grandfather’s marijuana. Trend. Pharmacol. Sci., 38, 257–276.
Cooper, Z.D. (2016) Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr. Psych. Rep., 18, 52.
Fattore, L. (2016) Synthetic cannabinoids - Further evidence supporting the relationship between cannabinoids and psychosis. Biol. Psych., 79, 539–548.
Gray, R., Bressington, D., Hughes, E. and Ivanecka, A. (2016) A systematic review of the effects of novel psychoactive substances ‘legal highs’ on people with severe mental illness. J. Psych. Ment. Health Nurs., 23, 267–281.
Springer, Y.P., Gerona, R., Scheunemann, E., Shafer, S.L., Lin, T., Banister, S.D. and McLaughlin, J.B. (2016) Increase in adverse reactions associated with use of synthetic cannabinoids - Anchorage, Alaska, 2015–2016. MMWR Morb. Mort. Wkly Rep., 65, 1108–1111.
White, C.M. (2017) The pharmacologic and clinical effects of illicit synthetic cannabinoids. J. Clin. Pharmacol., 57, 297–304.
Diez-Alarcia, R., Ibarra-Lecue, I., Lopez-Cardona, A.P., Meana, J., Gutierrez-Adan, A., Callado, L.F. and Uriguen, L. (2016) Biased agonism of three different cannabinoid receptor agonists in mouse brain cortex. Front. Pharmacol., 7, 415.
McPartland, J.M., Glass, M. and Pertwee, R.G. (2007) Metaanalysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br. J. Pharmacol., 152, 583–593.
Layer, R.T. (2001) Saturation analysis of ligand binding using a centrifugation procedure. Curr. Protoc. Neurosci., 2, 7.7.1–7.7.4.
Rossi, A.M. and Taylor, C.W. (2013) High-throughput fluorescence polarization assay of ligand binding to IP3 receptors. Cold Spring Harb. Prot., 2013, 938–946.
Martinez-Pinilla, E., Rabal, O., Reyes-Resina, I., Zamarbide, M., Navarro, G., Sanchez-Arias, J.A. and Franco, R. (2016) Two affinity sites of the cannabinoid subtype 2 receptor identified by a novel homogeneous binding assay. J. Pharmacol. Exp. Ther., 358, 580–587.
Hoa, X.D., Kirk, A.G. and Tabrizian, M. (2007) Towards integrated and sensitive surface plasmon resonance biosensors: a review of recent progress. Biosens. Bioelectron., 23, 151–160.
Piliarik, M., Vaisocherova, H. and Homola, J. (2009) Surface plasmon resonance biosensing. Methods Mol. Biol., 503, 65–88.
Cha, H.J., Lee, K., Song, M., Hyeon, Y., Hwang, J., Jang, C. and Jeong, H. (2014) Dependence potential of the synthetic cannabinoids JWH-073, JWH-081, and JWH-210: In vivo and in vitro approaches. Biomol. Ther. (Seoul), 22, 363–369.
Mella-Raipan, J., Hernandez-Pino, S., Morales-Verdejo, C. and Pessoa-Mahana, D. (2014) 3D-QSAR/CoMFA-based structure-affinity/selectivity relationships of aminoalkylindoles in the cannabinol CB1 and CB2 receptors. Molecules, 19, 2842–2861.
Myint, K.Z. and Xie, X.Q. (2015) Ligand biological activity predictions using fingerprint-based artificial neural networks (FANN-QSAR). Methods Mol. Biol., 1260, 149–164.
Cereghino, J.L. and Cregg, J.M. (2000) Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev., 24, 45–66.
Reilander, H. and Weiss, H.M. (1998) Production of G-protein-coupled receptors in yeast. Curr. Opin. Biotechnol., 9, 510–517.
Kim, T.K., Zhang, R., Feng, W., Cai, J., Pierce, W. and Song, Z.H. (2005) Expression and characterization of human CB1 cannabinoid receptor in methylotrophic yeast Pichia pastoris. Protein. Expr. Purif., 40, 60–70.
Presley, C.S., Abidi, A.H. and Moore, B.M., 2nd. (2016) Cannabinoid receptor 1 ligands revisited: Pharmacological assessment in the ACTOne system. Anal. Biochem., 498, 8–28.
Smoum, R., Baraghithy, S., Chourasia, M., Breuer, A., Mussai, N., Nttar-Namdar, M. and Bab, I. (2015) CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency. Proc. Natl. Acad. Sci. U.S.A., 112, 8774–8779.
Wiley, J.L., Marusich, J.A., Lefever, T.W., Antonazzo, K.R., Wallgren, M.T., Cortes, R.A. and Thomas, B.F. (2015) ABCHMINACA, AB-PINACA, and FUBIMINA: Affinity and potency of novel synthetic cannabinoids in producing Δ9-tetrahydrocannabinol-like effects in mice. J. Pharmacol. Exp. Ther., 354, 328–339.
Cha, H.J., Lee, K., Song, M., Hyeon, Y., Hwang, J., Jang, C., Ahn, J., Jeon, S., Kim, H., Kim, Y., Seong, W., Kang, H., Yoo, H.S. and Jeong, H. (2014) Dependence potential of the synthetic cannabinoids JWH-073, JWH-081, and JWH-210: in vivo and in vitro approaches. Biomol. Ther. (Seoul), 22, 363–369.
Roche, J.P., Bounds, S., Brown, S. and Mackie, K. (1999) A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization. Mol. Cell. Pharmacol., 56, 611–618.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Cha, H.J., Song, Y.J., Lee, D.E. et al. Receptor Binding Affinities of Synthetic Cannabinoids Determined by Non-Isotopic Receptor Binding Assay. Toxicol Res. 35, 37–44 (2019). https://doi.org/10.5487/TR.2019.35.1.037
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.5487/TR.2019.35.1.037